Celgene

FDA calls out 39 drug companies for allegedly blocking access to generics
FDA calls out 39 drug companies for allegedly blocking access to generics
Stat
JNJ
Actelion
Celgene
Gilead
Novartis
Pfizer
Valeant Pharmaceuticals
generics
FDA
Flag link:
Celgene Starts the Year With a Bang
Celgene Starts the Year With a Bang
Motley Fool
Celgene
earnings
Flag link:
Ex-Receptos CTO co-founds SD startup Escient, launching with $40M Series A
Ex-Receptos CTO co-founds SD startup Escient, launching with $40M Series A
Endpoints
Receptos
Celgene
Marcus Boehm
Escient
G-protein coupled receptors
Flag link:
Who do you trust? For doctors, it's Bristol Myers-Squibb and Biogen
Who do you trust? For doctors, it's Bristol Myers-Squibb and Biogen
Fierce Pharma
physicians
digital marketing
Bristol-Myers Squibb
Biogen
Celgene
Flag link:
Celgene's timeline for refiling ozanimod gets mixed reviews
Celgene's timeline for refiling ozanimod gets mixed reviews
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
FDA
Flag link:
Celgene Rises As Q1 Earnings, Sales Top Views
Celgene Rises As Q1 Earnings, Sales Top Views
Investors Business Daily
Celgene
earnings
Flag link:
Earnings Preview: What To Expect From Celgene On Friday
Earnings Preview: What To Expect From Celgene On Friday
Forbes
Celgene
earnings
Flag link:
4 Huge Pharma Deals in 4 Months Is Just the Beginning
4 Huge Pharma Deals in 4 Months Is Just the Beginning
Motley Fool
M&A
Takeda
Shire
Novartis
AveXis
Sanofi
Bioverativ
Celgene
Juno Therapeutics
Flag link:
A metabolite will make or break Celgene's ozanimod
A metabolite will make or break Celgene's ozanimod
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
metabolite
Flag link:
Immunotherapies, biosimilars to dominate next week of earnings
Immunotherapies, biosimilars to dominate next week of earnings
Biopharma Dive
AbbVie
AstraZeneca
Bristol-Myers Squibb
Celgene
Roche
Vertex Pharmaceuticals
Sanofi
earnings
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
CP Wire
Celgene
ozanimod
relapsing multiple sclerosis
MS
Flag link:
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
Motley Fool
Celgene
Bluebird Bio
beta thalassemia
LentiGlobin
luspatercept
Flag link:
Pfizer's Deal Potential Doesn't Stop at Bristol-Myers
Pfizer's Deal Potential Doesn't Stop at Bristol-Myers
Bloomberg
Pfizer
M&A
Bristol-Myers Squibb
Celgene
Eli Lilly
AstraZeneca
Flag link:
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Fierce Biotech
Celgene
M&A
Agios Pharmaceuticals
Jounce Therapeutics
Flag link:
Celgene, AbbVie extracted higher prices in Q4 as other pharmas netted less: report
Celgene, AbbVie extracted higher prices in Q4 as other pharmas netted less: report
Fierce Pharma
Celgene
AbbVie
drug pricing
Flag link:
Celgene Parts with COO Scott Smith “Effective Immediately”
Celgene Parts with COO Scott Smith “Effective Immediately”
Xconomy
Celgene
Scott Smith
Flag link:
Celgene, bluebird revise deal to co-develop CAR-T therapy
Celgene, bluebird revise deal to co-develop CAR-T therapy
Biopharma Dive
Celgene
Bluebird Bio
drug development
CAR-T
bb2121
Multiple Myeloma
Flag link:
Arena Pharmaceuticals Takes Aim at Celgene
Arena Pharmaceuticals Takes Aim at Celgene
Motley Fool
Arena Pharmaceuticals
Celgene
etrasimod
ozanimod
ulcerative colitis
Flag link:
Prothena, Celgene ink neuro R&D pact potentially worth $2B+
Prothena, Celgene ink neuro R&D pact potentially worth $2B+
Fierce Biotech
Prothena
Celgene
R&D
TDP-43
anti-tau antibodies
Alzheimer's disease
Flag link:
Why Amgen Shouldn't Use Its War Chest For A Celgene Megamerger
Why Amgen Shouldn't Use Its War Chest For A Celgene Megamerger
Investors Business Daily
Amgen
Celgene
M&A
Alexion
AstraZeneca
Flag link:

Pages